ONWARD
22.4.2021 14:32:04 CEST | Business Wire | Press release
ONWARD today announced the Company has successfully completed a $32M financing. The round was led by Invest-NL, the Dutch impact investor, and Olympic Investments, the private investment arm of the Onassis Foundation. Several additional new investors and all of ONWARD’s existing investors also participated in the financing, including leading medical technology investors LSP, INKEF Capital, Gimv, and Wellington Partners.
Proceeds from the financing will be used to fund the continued development and commercialization of ONWARD’s ARC Therapy. The company plans to commercialize two technology platforms, an implantable system called ARC-IM and an external system called ARC-EX. Both platforms are designed to deliver targeted, programmed stimulation of the spinal cord to restore movement, independence, and health in people with spinal cord injury, ultimately improving their quality of life. ARC-IM and ARC-EX have each been awarded Breakthrough Device Designation by the FDA. ARC-EX is currently undergoing clinical trials in the U.S., Canada, UK, and Western Europe in a pivotal study called Up-LIFT .
“We are deeply committed to developing and commercializing research breakthroughs, bringing them out of the laboratory and into the clinic,” said Dave Marver, Chief Executive Officer of ONWARD. “This funding will enable ONWARD to sustain our quest to help people with spinal cord injury enjoy life in every way that matters to them.”
“ONWARD’s ARC Therapies have the potential to significantly improve outcomes for those living with spinal cord injury,” said John de Koning, Partner at LSP. “The company’s ability to attract several prominent new investors and the broad participation of its existing shareholders demonstrates our expectations that the company has the technology, the team, and the promise to grow into a large and enduring business.”
About ONWARD
ONWARD (@onwdempowered ) is a medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury. ONWARD’s work builds on more than a decade of basic science and preclinical research conducted at the world’s leading neuroscience laboratories. ONWARD’s ARC Therapy, which can be delivered by implantable (ARC-IM) or external (ARC-EX) systems, is designed to deliver targeted, programmed stimulation of the spinal cord to restore movement and other functions in people with spinal cord injury, ultimately improving their quality of life. Both of ONWARD’s technology platforms have been awarded Breakthrough Device Designation by the FDA. The company’s first FDA pivotal trial, called Up-LIFT, commenced in January 2021 with plans to enroll 65 subjects at up to 15 centers worldwide.
ONWARD is headquartered at the High Tech Campus in Eindhoven, the Netherlands and the EPFL Innovation Park in Lausanne, Switzerland, with a growing U.S. presence in Boston, Massachusetts, USA. For additional information about the company, please visit ONWD.com and follow us on Twitter and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210422005099/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTTS Secures Strategic Engineering and R&D Agreement from Global Automotive OEM28.1.2026 08:30:00 CET | Press release
Key win in LTTS’ Mobility Segment across multiple vehicle technology domains L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, announced that it has secured a significant multi-year engagement in its Mobility segment from a leading automotive OEM. The strategic win further strengthens LTTS’ long-standing partnership with the premium automotive manufacturer and underscores its growing role in supporting next-generation mobility engineering. The engagement encompasses advanced software, connectivity and digital engineering services across multiple vehicle technology domains. LTTS will draw on its global engineering expertise, strong domain knowledge and proven delivery frameworks to support the customer’s evolving product and technology roadmap. This win reinforces LTTS’ comprehensive mobility engineering capabilities, spanning embedded systems, digital platforms, verification and validation, cloud integration, cybersecurity, and
SFI Health™ EMEA Announces the Launch in Poland of Equazen® Forte, Marking a New Chapter in Cognitive Support for Young Adults and Adults28.1.2026 08:00:00 CET | Press release
Equazen® Forte represents a strategic evolution of the brand, extending its clinically researched omega-3 based cognitive support product formulation beyond children to young adults and adults through pharmacies across Poland. SFI Health™ EMEA, the regional entity of SFI Health™, a global leader in natural healthcare, today is pleased to announce the launch of Equazen® Forte in Poland, a new concentrated omega 3 product formulation to be added to the Equazen® range designed to support the normal cognitive performance for young adults and adults. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260127646023/en/ Equazen® Forte: a key milestone in the brand’s long-term development strategy. Equazen® Forte represents a key milestone in the brand’s long-term development strategy. Traditionally recognized as a pediatric brain health expert, Equazen® is now evolving to support consumers across different life stages, addressing changi
Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse® G pTau 217 CSF Assay for Research Use Only28.1.2026 07:07:00 CET | Press release
H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G pTau 217 CSF assay for the fully automated LUMIPULSE® G immunoassay analyzers. This CLEIA (chemiluminescent enzyme immunoassay) assay is available for Research Use Only (RUO) and allows for the quantitative measurement of Tau phosphorylated at threonine 217 (pTau 217) in human cerebrospinal fluid (CSF) within just 35 minutes. Alzheimer’s disease (AD) is characterized by the accumulation of neurofibrillary tangles in the brain, composed of hyperphosphorylated tau, and amyloid plaques, consisting of distinct β-amyloid peptides. CSF pTau217 has emerged as an early biomarker for neuropathological changes associated with AD. This new immunoassay further strengthens Fujirebio’s growing portfolio of neurological biomarkers and reinforces the company’s leading position in the advancement of associated research tools and diagnostics. “By adding pTau 217 CSF to our neuro portfol
NTT, DOCOMO, and NTT DATA to Exhibit at MWC Barcelona 202628.1.2026 07:00:00 CET | Press release
The NTT Group, comprising NTT, Inc., NTT DOCOMO, INC., and NTT DATA Group Corporation, announced today that they will jointly exhibit at MWC Barcelona 2026, the world’s largest connectivity event, to be held in Barcelona, Spain, from March 2 to March 5, 2026. At this event, the NTT Group will showcase its technological capabilities and foster deeper connections with leading global companies. Under the unified concept introduced following the corporate identity (CI) renewal on July 1, 2025, the NTT Group aims to strengthen its global brand presence and expand its business internationally. This will be the NTT Group’s first joint exhibition in seven years since 2019. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260127239513/en/ The NTT Group Booth at MWC Barcelona 2026 Under the theme, “Photonics Unlocks an Intelligent Power-Optimized Future,” the NTT Group will present its initiatives centered around IOWN1 optical technolog
Multi-Color Corporation Announces Recapitalization to Reset Balance Sheet and Position Company for Long-Term Growth and Investment27.1.2026 22:09:00 CET | Press release
MCC Enters into Restructuring Support Agreement to Eliminate Approximately $3.9 Billion of Outstanding Funded Debt, Reduce More than $330 Million of Cash Interest Expense in 2026 and Extend Long-Term Debt Maturities to 2033Restructuring Supported by CD&R and More Than Supermajority of Senior Secured Lenders Who Have Agreed to Backstop a Nearly $890 Million Investment; Provides More Than $500 Million of New Liquidity to Support Long-Term Growth and Investment Upon EmergenceLaunches Consent Solicitation and Expects to Implement Restructuring Through “Prepackaged” Chapter 11 Process; Restructuring Support Agreement Provides for CD&R to Be Controlling ShareholderAll Trade Vendors Expected to be Paid in Full; All Global Operations and Service to Customers Expected to Continue Without Interruption Multi-Color Corporation (“MCC” or the “Company”), a global leader in prime label solutions, today announced strategic actions to further position the Company for long-term growth and investment to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom